We next assessed the performance of EaSIeR on seven different independent datasets, including four different cancer types, with patients treated with anti-PD-1 or anti-PD-L1 immunotherapy (experimental procedures; Table S5).91, 92, 93, 94, 95, 96, 97 Pre-therapy RNA-seq data were provided as input to EaSIeR, which derived patent-specific, system-based signatures of the TME. Here, CD274 is linked to cancer.